in the absence of a submission from the holder of the marketing authorisation:
ranibizumab (Lucentis®) is not recommended for use within NHSScotland.
Indication under review: treatment of proliferative diabetic retinopathy in adults.
The holder of the marketing authorisation has not made a submission to SMC regarding this product in this indication. As a result we cannot recommend its use within NHSScotland.
Download detailed advice610KB (PDF)
- Medicine name:
- ranibizumab (Lucentis)
- SMC ID:
Treatment of proliferative diabetic retinopathy in adults.
- Pharmaceutical company
- Novartis Pharmaceuticals UK Ltd
- Submission type
- Non submission
- Date advice published
- 10 February 2020